Table 2.
Sites of distribution of unifocal and multifocal genital warts and recurrences (women with primary diagnosis of genital warts between 2003 and 2009)
| Sites of distribution | Number of patients (%) | Recurrence (%) |
|---|---|---|
| All | 825 | 141 (17.1%) |
| Unifocal | 195 (23.6%) | 22 (11.3%) |
| Vulva | 150 (18.2%) | 15 (10.0%) |
| Perineum/perianal | 20 (2.4%) | 2 (10.0%) |
| Vagina | 18 (2.2%) | 5 (27.8%) |
| Cervix | 7 (0.9) | 0 (0%) |
| Multifocal | 630 (76.4%) | 119 (18.9%) |
| Vulva–perineum/perianal | 125 (15.2%) | 22 (17.6%) |
| Vagina–vulva–perineum/perianal | 100 (12.1%) | 18 (18.0%) |
| Vagina–vulva | 97 (11.8%) | 15 (15.5%) |
| Vulva–perineum/perianal–anus | 82 (9.9%) | 14 (17.1%) |
| Vagina–vulva–perineum/perianal–anus | 77 (9.3%) | 18 (23.4%) |
| Cervix–vagina–vulva–perineum/perianal–anus | 25 (3.0%) | 6 (24.0%) |
| Cervix–vagina–vulva | 23 (2.8%) | 5 (21.7%) |
| Cervix–vagina–vulva–perineum/perianal | 20 (2.4%) | 4 (20.0%) |
| Perineum/perianal–anus | 16 (1.9%) | 2 (12.5%) |
| Cervix–vulva | 11 (1.3%) | 4 (36.4%) |
| Vagina–vulva–anus | 10 (1.2%) | 3 (30.0%) |
| Other combinations | 44 (5.3%) | 8 (18.2%) |
| Number of affected sites | ||
| One site | 195 (23.6%) | 22 (11.3%) |
| Two sites | 269 (32.6%) | 45 (16.7%) |
| Three sites | 226 (27.4%) | 44 (19.5%) |
| Four sites | 110 (13.3%) | 24 (21.8%) |
| Five sites | 25 (3.0%) | 6 (24.0%) |